Answers are grounded in this paper and cite their sources.
A pilot trial shows dolutegravir improves neurological outcomes in participants with HTLV-1, suggesting its potential use for treatment.
In this pilot randomized trial, DTG use was associated with significantly reduced HPVL and improvement in neurofunctional and immunological characteristics of participants in exploratory analyses. These findings provide evidence supporting the use of integrase inhibitors for HTLV-1 infection.
No takes yet. Share an insight, caveat, or question.
Brites et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: